Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that high skin expression of amphiregulin in acute graft-versus-host disease was associated with severe disease grade, poor overall survival, and increased non-relapse mortality.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

In this study, a topical lotion containing Redensyl and Sepicontrol A5 demonstrated effectiveness for treating androgenetic alopecia over 24 weeks, with 73.1% of users seeing moderate improvement and notable increases in hair cycle ratios, alongside enhanced quality of life and satisfaction.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This study found that Asiasari radix extract may reduce hyperalgesia in mice by modulating NMDA and GABAA receptor activities without affecting cyclooxygenase activity.

This study identified a compound heterozygous mutation in a hairless rhesus macaque, which was associated with skin abnormalities similar to those in hairless mice and humans with APL.

This review highlights various pharmacological activities of the herbal plant Hansraj (Adiantum capillus-veneris), including antioxidant, wound healing, anti-microbial, and anti-diabetic effects, but stresses the need for further research and clinical trials to confirm these potential benefits and safety concerns.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

This study identified multiple mutations in the 5 alpha-reductase-2 gene among male pseudohermaphrodites in the Dominican Republic, suggesting they do not share a common ancestry.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

5α-Reductase helps regulate hormone action in toad testes, especially during breeding season.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This article reviews the effectiveness of adrenal cortex compounds E and F in treating various connective tissue disorders and reports no new clinical findings.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

This study found that supraphysiological and physiological androgen levels inhibited U937 macrophages' phagocytosis of MRSA compared to untreated controls, but AR antagonism reversed this effect, suggesting targeting AR or using 5alpha-reductase inhibitors might aid bacterial clearance in elderly males' chronic wounds.

The study observed that mRAGE expression is prevalent in keratinocytes of the healthy human epidermis and may regulate inflammation and apoptosis to maintain skin homeostasis rather than responding to aging processes.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

This review observes higher ACE2 expression in myocardial and lung tissues of heart failure and COPD patients but finds no link between RAAS inhibitors and COVID-19 severity.